1 / 38

RECTAL CARCINOMA

RECTAL CARCINOMA. ELSHAMI ELAMIN, MD Central Care Cancer Center Newton, KS-USA. RISK FACTORS. Dietary factors Fat ? Fiber ? Calcium ? Vitamins (E, -carotene) Aspirin/NSAIDs (Cox inhibitors) Sulindac reduces polyps in FAP pts Aspirin lower risk of CRC. RISK FACTORS.

marcy
Télécharger la présentation

RECTAL CARCINOMA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RECTAL CARCINOMA ELSHAMI ELAMIN, MD Central Care Cancer Center Newton, KS-USA

  2. RISK FACTORS • Dietary factors • Fat • ? Fiber • ? Calcium • ? Vitamins (E, -carotene) • Aspirin/NSAIDs (Cox inhibitors) • Sulindac reduces polyps in FAP pts • Aspirin lower risk of CRC

  3. RISK FACTORS • Genetic Factors • FAP(APC gene = Tumor suppressor gene) • 1-2% of CRC • Invasive cancer occurs at ~ 42Y • HNPCC (MMR mutations) • Hx of > 3 family members involving 2 generations with one diagnosed before age 50 • 4-6% incidence • Rt-sided cancer • Caused by defective DNA mismatch repair genes

  4. Steps for Colorectal Carcinogenesis 1- Mutation at MCC and APC genes 2- K-ras oncogene activates adenoma to carcinoma 3- Mutation of p53 tumor suppressor gene

  5. SCREENING • Patients with average risk • Asymptomatic • >50Y • No colorectal risk factors • FOBT (33% reduction in mortality) • Flexible sig (60-80% reduction in mortality) • Double-contrast BE • Colonoscopy (Gold standard)

  6. Patients with increased Risk • First-degree relative with CRC or adenomatous polyps • FAP • F.H. of HNPCC • Adenomatous polyps • CRC • IBD

  7. Hereditary CRC syndromesScreening and Management • FAP • Genetic counseling/gene testing • Is cost-effective • Genetic mutation not identified: • Flex sig at puberty and annualy • Colonoscopy if +ve sig • +ve FAP • Total colectomy

  8. HNPCC (Lynch syndrome) • Lynch I: • No associated cancers • Lynch II: • Associated with ovarian, uterine cancers • Genetic testing • Difficult due to multiple mutations • MLH1, MSH2 mutations • Screening begin at 20Y and every 1-2Y • Genetically +ve: Consider colectomy/TAH/BSO

  9. Work-up • Laboratory: • LFTs • CBC, Iron profile • CEA • Preoperative CT scan • Colon cancer: Adjacent organ invasion/Liver met • Rectal: Adjacent organ invasion/LN spread • For preop RT

  10. MRI • Bowel wall penetration • MRI: 64%, CT: 62% • Sensitivity for LN met: 15-40% • Endorectal surface coil MRI for N1 • 72% specificity

  11. Transrectal US • Evaluation for preop cheop/RT • Only 83-88% specific in separating T-T2 from T3-T4 • LN specificity • 28% for 5mm LN • 62% for 7mm

  12. CEA scan • Coupled with standard CT • Can predict preop respectability

  13. PET Scan • Staging • Restaging • 91% sensitivity, ~ 100% specificity for pelvic disease (CT: 52%, 80%) • 95% sensitivity for liver disease (CT 74%)

  14. Staging • Dukes’ classification • Based on depth of invasion and LN • A: Limited to bowel wall • B: Extrarectal tissues • C: LN + • Modified Dukes’ (Astler-Coller system) • C1 and C2

  15. TNM • Stage I: T1 (invade submucosa) A T2 (invade muscul propria) B1 • Stage II: T3 (invade through musc propria B2 into subserosa or nonperit. Tissue) T4 (perforate ves perit or B3 invade adjacent structure) • Stage III: N1 (1-3 pericolic/rectal) N2 (> 4) C N3 (along vascular trunk) • Stage IV: M1

  16. Prognostic Factors • Adjacent tissue or vascular invasion • Nodal status • Micromets (<5mm) same as enlarged LN • 4 LN vs >4 • ? Cellular pathologic factors • S-phase, ploidy • Liver mets • Normal LFTs: 18 month med S • Elevated Bil: 6 wks med S

  17. Prognostic Factors • CEA • Weak prognostic factor • Persistant CEA elevation = Residual dz • May increase initially during adjuvant • Not prognostic factors • Age, Sex, Tumor size

  18. Rectal CaSurgical Treatment • Abdominal Perineal Resection (APR) • Permanent Colostomy • Sphincter Preservation

  19. APR • Based on: • Rectal cancer spread via lymphatic pathways in proximal, lateral and distal direction • Decreases local recurrence • Improve survival • Permanent colostomy

  20. APR • Candidates • Primary sphincter dysfunction • Tumor invading anal canal • High risk for local recurrence • Bulky disease • Poorly differentiated involving lower 1/3 • Direct extension into adjacent organs

  21. Total Mesorectal Excision (TME) • Tumor spread into adjacent mesorectum • >2cm distal extension from the margin carries poor prognosis • Decreases local recurrence • Improve survival • Standard for mid and lower rectal cancers • Preserves pelvic autonomic nerve function

  22. Surgical Options for Sphincter Preservation

  23. Local Excision • Lower 1/3 early rectal cancer (T1) • < 4 cm in diameter • Mobile lesion • Involve < 1/4 of circumference of bowel • Moderate to well differentiated • From 2 prospective Trials • T1 : Local excision alone • T2 : Local excision + CT/RT

  24. Local Excision with RT • Indications • T2 • Lymphatic/vascular invasion • Poor histology • Positive margin • Fragmented resection

  25. Endocavitary RT • Selection criteria • Distal lesion • No disease beyond bowel wall • No major extension to anal canal • T < 3x5 cm • Local failure • 5-20% • Salvage radical surgery

  26. Low Anterior Resection (LAR) 1- Bowel divided at 5cm above rectal tumor 2- Ligation of superior hemorrhoidal artery 3- Total Mesorectal Excision (TME) for mid/lower rectal tumors 4- 11/2 - 2cm distal margin 5- Colo-Rectal anastomosis

  27. Colonic J-Pouch • For low rectal cancer • To prevent incontinence/urgency

  28. APR vs Sphincter Sparing Resections (SSR) in Mid-rectal cancers 5 Y S % APR SSR Mayo et al 69 72 Patel et al 56 64 Jones/Thomson 52 67 Williams/Johnston 62 74 • Local recurrence: APR 8%, SSR 11% (not significant)

  29. ADJUVANT THERAPY

  30. Rectal Cancer • Incidence of local failure after resection • T1, T2N0: <10% • T3N0: 15-30% • T3N1: 35-50% • T3-T4N1: 60% • No successful salvage procedure

  31. Pre-Operative RT • Improves local control (Several studies) • Improves OS (Only one study) • Downside • Overtreatment of T1, T2 • Use Transrectal US • Treatment of patient with hepatic mets • Use spiral CT

  32. Locally Advanced Rectal Cancer • PreOp external RT + IntraOp RT • 67%5Y local control, 57% DFS • PreOp RT or Chemo/RT • 70-85% resectability and sphincter sparing surgery

  33. Locally Recurrent Disease • Treatment options depend on • Local extent • Isolated suture line recurrence after LAR • APR + Chemo/RT if no prior RT • Local recurrence without prior RT • PreOp chemo/RT, Surgery + IORT • Poor long-term DFS even with complete resection • Symptoms • Distant mets • Prior adjuvant therapy

  34. CEA • 43-89% Sensitivity, 70-90% specificity • PreOp elevation predicts worse prognosis • Not useful in determining the need for adjuvant • Elevation correlates with Dukes’ stage • Persistent 1-month postOp elevation predicts mets • Monitor CEA q2-3 moths during chemo • Modest elevation • Fatty liver infiltration, hepatitis, pneumonia, GE

  35. Systemic Chemotherapy

  36. 5-FU • 5 days IVP regimen: • Mucositis, diarrhea, neutropenia • Wkly IVP regimen: • Diarrhea • CI regimen/Capecitabine: • Hand-foot syndrome, mucositis • Diarrhea or neutropenia • High dose regimen 24-48hrs • Altered MS, angina-like chest pain

  37. Oxaliplatin = Irinotecan • FOLFOX • FOLFIRI • XELOX • XELIRI • AVASTIN/ZALTRAP • ERBITUX/VECTIBIX • REGORAFENIB

  38. Regional Therapy(Liver Mets) • HAI of FUDR via an implanted pump • Addition of dexamthazone reduces sclerosing cholangitis and enhances RR • Chemoembolization • 3mg/ml Adria + 3mg/ml MC + 10mg/ml CDDP with bovine collagen • Postembolization syndrome (fever, RtUQ pain, N/V, lethargy, hematologic toxicity) • Resection

More Related